Researchers found that administration of the drug rapamycin in mice was associated with increased beta-amyloid plaques. This is one of the hallmark pathologies of Alzheimer’s disease. The study authors caution that rapamycin’s effects in beta-amyloid-associated Alzheimer’s must be studied more carefully.